Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Insights
  5. Ipo

IPO

Evaluate

July 06, 2023

Biopharma's flotation haul creeps higher

Life is returning to the IPO scene, but the recovery is slow and uncertain.

April 06, 2023

Floating biotechs prompt tiny sparks of hope

But with only four IPOs so far this year, there is no disguising a moribund market.

Article image
Vantage logo
January 13, 2023

An annus horribilis for medtech flotations

Bausch & Lomb saves 2022's medtech IPO scene from washout as markets close for new entrants.

Article image
Vantage logo
January 05, 2023

Flotations fail to bounce back

2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.

Article image
Vantage logo
October 04, 2022

The biopharma flotation remains a rare beast

Few developers are feeling bold enough to brave the markets, though the bigger deals are finding some support.

Article image
Vantage logo
July 22, 2022

Venture financing holds steady for device makers

Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.

Article image
Vantage logo
July 07, 2022

Biotech flotations plunge to a 10-year low

The sector must hope that the bottom has been reached.

Article image
Vantage logo
April 07, 2022

Flotations tank in the first quarter

A correction – as long as it is not too severe – might not be a bad thing for the sector.

Article image
Vantage logo
January 20, 2022

Medical device groups float – then sink

Medtechs rushed for the markets last year, but had an uneasy time once there.

Article image
Vantage logo
January 13, 2022

After a record year, where next for biopharma flotations?

2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.

Article image
Vantage logo
October 05, 2021

Biotech listings show signs of a slowdown

2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...
Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up